The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | The role of gut microbiome on immunotherapy outcomes in lung cancer
Amit Kulkarni, MBBS, University of Minnesota, Minneapolis, MN, discusses the crucial role of gut microbiome diversity in clinical outcomes. Findings from various preclinical and clinical studies indicate that antibiotic exposure during immunotherapy may adversely affect patient outcomes, including progression-free survival (PFS) and overall survival (OS). Data from a neoadjuvant study in patients with breast cancer demonstrate that those with prior antibiotic exposure had lower rates of pathological complete response (CR), highlighting the effects of antibiotics beyond immunotherapy. While the precise mechanisms remain unclear, that the gut microbiome may modulate immune responses through tertiary and secondary lymphoid structures within the tumour microenvironment (TME). This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
